natgillin/translations-raw huggingface dataset:
Corbilta 150 mg/37.5 mg/200 mg: brownish or greyish red, elongated-ellipse shaped, unscored filmcoated tablets marked with ‘LCE 150' on one side. 
Corbilta 150 mg/37,5 mg/200 mg: smećkasto- ili sivkasto-crvene, izdužene filmom obložene tablete u obliku elipse, bez ureza, s oznakom "LCE 150" na jednoj strani.
Corbilta 75 mg/18.75 mg/200 mg tablet comes in five different pack sizes (10, 30, 100, 130 or 175 tablets). 
Corbilta 75 mg/18,75 mg/200 mg tablete dolazi u pet različitih veličina pakiranja (10, 30, 100, 130, ili 175 tableta).
Corbilta 175 mg/43.75 mg/200 mg: light brownish red, oval, unscored film-coated tablets marked with ‘LCE 175' on one side. 
Corbilta 175 mg/43,75 mg/200 mg: svijetlo smećkasto-crvene, ovalne filmom obložene tablete, bez ureza, s oznakom "LCE 175" na jednoj strani.
Corbilta contains sucrose (1.89 mg/tablet). 
Corbilta sadrži saharozu (1,89 mg/tableti).
Corbilta 125 mg/31.25 mg/200 mg: light brownish red, oval film-coated tablets marked with ‘LCE 125' on one side. 
Corbilta 125 mg/31,25 mg/200 mg: svijetlo smećkasto-crvene, ovalne filmom obložene tablete, s oznakom "LCE 125" na jednoj strani.
Corbilta contains sucrose (2.3 mg/tablet). 
Corbilta sadrži saharozu (2,3 mg/tableti).
Corbilta 75 mg/18.75 mg/200 mg: light brownish red, oval film-coated tablets marked with ‘LCE 75' on one side. 
Corbilta 75 mg/18,75 mg/200 mg: svijetlo smećkasto-crvene, ovalne filmom obložene tablete, s oznakom "LCE 75" na jednoj strani.
Corbilta 125 mg/31.25 mg/200 mg tablet comes in five different pack sizes (10, 30, 100, 130 or 175 tablets). 
Corbilta 125 mg/31,25 mg/200 mg tablete dolazi u pet različitih veličina pakiranja (10, 30, 100, 130, ili 175 tableta).
Serious events of gastrointestinal haemorrhage (uncommon) and angioedema (rare) have been identified from the clinical trials with Corbilta or entacapone combined with levodopa/DDC inhibitor. 
U kliničkim ispitivanjima s Corbiltom ili entakaponom u kombinaciji s levodopom/DDCinhibitorom otkriveni su ozbiljni događaji gastrointestinalnog krvarenja (manje često) i angioedema (rijetko).
Corbilta 200 mg/50 mg/200 mg tablet comes in five different pack sizes (10, 30, 100, 130 or 175). 
Corbilta 200 mg/50 mg/200 mg tablete dolazi u pet različitih veličina pakiranja (10, 30, 100, 130, ili 175 tableta).
Corbilta 75 mg/18.75 mg/200 mg film-coated tablets levodopa/carbidopa/entacapone 
Corbilta 75 mg/18,75 mg/200 mg filmom obložene tablete levodopa/karbidopa/entakapon
- Each Corbilta 125 mg/31.25 mg/200 mg tablet contains 125 mg of levodopa, 31.25 mg of carbidopa and 200 mg of entacapone. 
- Jedna Corbilta 125 mg/31,25 mg/200 mg tableta sadrži 125 mg levodope, 31,25 mg karbidope i 200 mg entakapona.
- Each Corbilta 75 mg/18.75 mg/200 mg tablet contains 75 mg of levodopa, 18.75 mg of carbidopa and 200 mg of entacapone. 
- Jedna Corbilta 75 mg/18,75 mg/200 mg tableta sadrži 75 mg levodope, 18,75 mg karbidope i 200 mg entakapona.
Corbilta 50 mg/12.5 mg/200 mg: brownish or greyish red, round, convex unscored film-coated tablets marked with ‘LCE 50' on one side. 
Corbilta 50 mg/12,5 mg/200 mg: smećkasto ili sivkasto-crvene, okrugle, konveksne filmom obložene tablete, bez ureza, s oznakom "LCE 50" na jednoj strani.
- Each Corbilta 175 mg/43.75 mg/200 mg tablet contains 175 mg of levodopa, 43.75 mg of carbidopa and 200 mg of entacapone. 
- Jedna Corbilta 175 mg/43,75 mg/200 mg tableta sadrži 175 mg levodope, 43,75 mg karbidope i 200 mg entakapona.
Corbilta 175 mg/43.75 mg/200 mg tablet comes in five different pack sizes (10, 30, 100, 130 or 175 tablets). 
Corbilta 175 mg/43,75 mg/200 mg tablete dolazi u pet različitih veličina pakiranja (10, 30, 100, 130, ili 175 tableta).
Initiation of Corbilta may be considered at corresponding doses to current treatment in some patients with Parkinson's disease and end-of-dose motor fluctuations, who are not stabilised on their current standard release levodopa/DDC inhibitor treatment. 
U nekih bolesnika s Parkinsonovom bolešću i motoričkim fluktuacijama na kraju intervala doziranja, koji nisu stabilizirani trenutnim liječenjem levodopom/DDC-inhibitorom sa standardnim oslobađanjem, može se razmotriti uvođenje Corbilte u dozama odgovarajućim trenutnoj terapiji.
Corbilta 100 mg/25 mg/200 mg: brownish or greyish red, oval, unscored film-coated tablets marked with ‘LCE 100' on one side. 
Corbilta 100 mg/25 mg/200 mg: smećkasto ili sivkasto-crvene, ovalne filmom obložene tablete, bez ureza, s oznakom "LCE 100" na jednoj strani.
Corbilta 200 mg/50 mg/200 mg: dark brownish red, oval, unscored film-coated tablets marked with ‘LCE 200' on one side. 
Corbilta 200 mg/50 mg/200 mg: tamno smećkasto-crvene, ovalne filmom obložene tablete, bez ureza, s oznakom "LCE 200" na jednoj strani.
- Each Corbilta 100 mg/25 mg/200 mg tablet contains 100 mg of levodopa, 25 mg of carbidopa and 200 mg of entacapone. 
- Jedna Corbilta 100 mg/25 mg/200 mg tableta sadrži 100 mg levodope, 25 mg karbidope i 200 mg entakapona.
- Each Corbilta 50 mg/12.5 mg/200 mg tablet contains 50 mg of levodopa, 12.5 mg of carbidopa and 200 mg of entacapone. 
- Jedna Corbilta 50 mg/12,5 mg/200 mg tableta sadrži 50 mg levodope, 12,5 mg karbidope i 200 mg entakapona.
- Each Corbilta 150 mg/37.5 mg/200 mg tablet contains 150 mg of levodopa, 37.5 mg of carbidopa and 200 mg of entacapone. 
- Jedna Corbilta 150 mg/37,5 mg/200 mg tableta sadrži 150 mg levodope, 37,5 mg karbidope i 200 mg entakapona.
Some patients experience severe abnormal involuntary movements (dyskinesias), mood swings or other side effects after taking large doses of Corbilta. 
U nekih se bolesnika nakon uzimanja velikih doza lijeka Corbilta javljaju vrlo izražene neuobičajene nevoljne kretnje (diskinezije), promjene raspoloženja ili druge nuspojave.
Corbilta contains sucrose (1.9 mg/tablet). 
Corbilta sadrži saharozu (1,9 mg/tableti).
How to transfer patients taking levodopa/DDC inhibitor (carbidopa or benserazide) preparations and entacapone tablets to Corbilta a. Patients who are currently treated with entacapone and with standard release levodopa/carbidopa in doses equal to Corbilta tablet strengths can be directly transferred to corresponding Corbilta tablets. 
Kako na Corbiltu prebaciti bolesnike koji primaju preparate levodope/DDC-inhibitora (karbidopa ili benzerazid) i entakapon tablete a.
Corbilta 175 mg/43.75 mg/200 mg film-coated tablets Levodopa/carbidopa/entacapone 
Corbilta 175 mg/43,75 mg/200 mg filmom obložene tablete levodopa/karbidopa/entakapon
Corbilta 125 mg/31.25 mg/200 mg film-coated tablets Levodopa/carbidopa/entacapone 
Corbilta 125 mg/31,25 mg/200 mg filmom obložene tablete levodopa/karbidopa/entakapon
Corbilta contains sucrose (1.6 mg/tablet). 
Corbilta sadrži saharozu (1,6 mg/tableti).
- Each Corbilta 200 mg/50 mg/200 mg tablet contains 200 mg of levodopa, 50 mg of carbidopa and 200 mg of entacapone. 
- Jedna Corbilta 200 mg/50 mg/200 mg tableta sadrži 200 mg levodope, 50 mg karbidope i 200 mg entakapona.
If you get any side effects talk to your doctor or pharmacist. 
Ako primijetite bilo koju nuspojavu, potrebno je obavijestiti svog liječnika ili ljekarnika.
Corbilta contains sucrose (1.2 mg/tablet). 
Corbilta sadrži saharozu (1,2 mg/tableti).
Corbilta contains sucrose (1.4 mg/tablet). 
Corbilta sadrži saharozu (1,4 mg/tableti).
Corbilta 100 mg/25 mg/200 mg film-coated tablets Levodopa/carbidopa/entacapone 
Corbilta 100 mg/25 mg/200 mg filmom obložene tablete levodopa/karbidopa/entakapon
EU/1/13/859/007 10 film-coated tablets EU/1/13/859/008 30 film-coated tablets EU/1/13/859/009 100 film-coated tablets EU/1/13/859/010 130 film-coated tablets EU/1/13/859/011 175 film-coated tablets 
EU/1/13/859/007 10 filmom obloženih tableta EU/1/13/859/008 30 filmom obloženih tableta EU/1/13/859/009 100 filmom obloženih tableta EU/1/13/859/010 130 filmom obloženih tableta EU/1/13/859/011 175 filmom obloženih tableta
Corbilta 150 mg/37.5 mg/200 mg film-coated tablets Levodopa/carbidopa/entacapone 
Corbilta 150 mg/37,5 mg/200 mg filmom obložene tablete levodopa/karbidopa/entakapon
The doses of other antiparkinsonian medicinal products may need to be adjusted when Corbilta treatment is substituted for a patient currently not treated with entacapone. 
Kod prelaska liječenja na Corbiltu u bolesnika koji se trenutno ne liječe entakaponom, može biti potrebno prilagoditi doze drugih antiparkinsonika.
Corbilta 50 mg/12.5 mg/200 mg film-coated tablets Levodopa/carbidopa/entacapone 
Corbilta 50 mg/12,5 mg/200 mg filmom obložene tablete levodopa/karbidopa/entakapon
Corbilta 200 mg/50 mg/200 mg film-coated tablets Levodopa/carbidopa/entacapone 
Corbilta 200 mg/50 mg/200 mg filmom obložene tablete levodopa/karbidopa/entakapon
EU/1/13/859/023 10 film-coated tablets EU/1/13/859/024 30 film-coated tablets EU/1/13/859/025 100 film-coated tablets EU/1/13/859/026 130 film-coated tablets EU/1/13/859/027 175 film-coated tablets EU/1/13/859/028 250 film-coated tablets 
EU/1/13/859/023 10 filmom obloženih tableta EU/1/13/859/024 30 filmom obloženih tableta EU/1/13/859/025 100 filmom obloženih tableta EU/1/13/859/026 130 filmom obloženih tableta EU/1/13/859/027 175 filmom obloženih tableta EU/1/13/859/028 250 filmom obloženih tableta
- The ingredients in the film-coating are glycerol (85 per cent) (E422), hypromellose, magnesium stearate, polysorbate 80, red iron oxide (E172), sucrose and titanium dioxide (E171). 
- Drugi sastojci u ovojnici tablete su glicerol (85-postotni) (E422), hipromeloza, magnezijev stearat, polisorbat 80, crveni željezov oksid (E172), saharoza i titanijev dioksid (E171).
EU/1/13/859/001 10 film-coated tablets EU/1/13/859/002 30 film-coated tablets EU/1/13/859/003 100 film-coated tablets EU/1/13/859/004 130 film-coated tablets EU/1/13/859/005 175 film-coated tablets EU/1/13/859/006 250 film-coated tablets 
EU/1/13/859/001 10 filmom obloženih tableta EU/1/13/859/002 30 filmom obloženih tableta EU/1/13/859/003 100 filmom obloženih tableta EU/1/13/859/004 130 filmom obloženih tableta EU/1/13/859/005 175 filmom obloženih tableta EU/1/13/859/006 250 filmom obloženih tableta
EU/1/13/859/018 10 film-coated tablets EU/1/13/859/019 30 film-coated tablets EU/1/13/859/020 100 film-coated tablets EU/1/13/859/021 130 film-coated tablets EU/1/13/859/022 175 film-coated tablets 
EU/1/13/859/018 10 filmom obloženih tableta EU/1/13/859/019 30 filmom obloženih tableta EU/1/13/859/020 100 filmom obloženih tableta EU/1/13/859/021 130 filmom obloženih tableta EU/1/13/859/022 175 filmom obloženih tableta
EU/1/13/859/034 10 film-coated tablets EU/1/13/859/035 30 film-coated tablets EU/1/13/859/036 100 film-coated tablets EU/1/13/859/037 130 film-coated tablets EU/1/13/859/038 175 film-coated tablets 
EU/1/13/859/034 10 filmom obloženih tableta EU/1/13/859/035 30 filmom obloženih tableta EU/1/13/859/036 100 filmom obloženih tableta EU/1/13/859/037 130 filmom obloženih tableta EU/1/13/859/038 175 filmom obloženih tableta
- The ingredients in the film-coating are glycerol (85 per cent) (E422), hypromellose, magnesium stearate, polysorbate 80, red iron oxide (E172), sucrose, titanium dioxide (E171), and yellow iron oxide (E172). 
- Drugi sastojci u ovojnici tablete su glicerol (85-postotni) (E422), hipromeloza, magnezijev stearat, polisorbat 80, crveni željezov oksid, (E172), saharoza, titanijev dioksid (E171) i žuti željezov oksid (E172).
EU/1/13/859/029 10 film-coated tablets EU/1/13/859/030 30 film-coated tablets EU/1/13/859/031 100 film-coated tablets EU/1/13/859/032 130 film-coated tablets EU/1/13/859/033 175 film-coated tablets 
EU/1/13/859/029 10 filmom obloženih tableta EU/1/13/859/030 30 filmom obloženih tableta EU/1/13/859/031 100 filmom obloženih tableta EU/1/13/859/032 130 filmom obloženih tableta EU/1/13/859/033 175 filmom obloženih tableta
EU/1/13/859/012 10 film-coated tablets EU/1/13/859/013 30 film-coated tablets EU/1/13/859/014 100 film-coated tablets EU/1/13/859/015 130 film-coated tablets EU/1/13/859/016 175 film-coated tablets EU/1/13/859/017 250 film-coated tablets 
EU/1/13/859/012 10 filmom obloženih tableta EU/1/13/859/013 30 filmom obloženih tableta EU/1/13/859/014 100 filmom obloženih tableta EU/1/13/859/015 130 filmom obloženih tableta EU/1/13/859/016 175 filmom obloženih tableta EU/1/13/859/017 250 filmom obloženih tableta
- The active substances of Corbilta are levodopa, carbidopa and entacapone. 
Corbilte su levodopa, karbidopa i entakapon.
Protelos is taken as one sachet once a day. 
Protelos se uzima kao jedna vrećica jedanput na dan.
The full EPAR for Protelos can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Cjelovito Europsko javno izvješće o ocjeni dokumentacije o lijeku (EPAR) za lijek Protelos nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The European Commission granted a marketing authorisation valid throughout the European Union for Protelos on 21 September 2004. 
Europska komisija izdala je odobrenje za stavljanje u promet koje za lijek Protelos vrijedi na prostoru Europske unije od 21. rujna 2004.
What measures are being taken to ensure the safe and effective use of Protelos? 
Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Protelos?
Protelos should be taken at least two hours after food, milk, milk products or calcium supplements, preferably at bedtime. 
Protelos treba uzeti barem 2 sata nakon hrane, mlijeka, mliječnih proizvoda ili nadopune kalcija, po mogućnosti u vrijeme odlaska na spavanje.
Other information about Protelos 
Ostale informacije o lijeku Protelos
The company will also conduct a study to evaluate the effectiveness of the measures that have been put in place to reduce risk of heart and circulatory problems. 
Tvrtka će također provesti ispitivanje za procjenu učinkovitosti uspostavljenih mjera za smanjivanje rizika od srčanih i krvožilnih problema.
Protelos is intended for long-term use. 
Protelos je namijenjen dugotrajnoj primjeni.
However, when looking only at women of 74 years of age or older with particularly weak thighbones, the results suggested a reduction of the risk of breaks in the hip with Protelos. 
Međutim, ako se uzmu u obzir samo žene starije od 74 godine s posebno slabom bedrenom kosti, rezultati pokazuju smanjenje rizika od prijeloma kuka s lijekom Protelos.
In order to reduce the risk of heart attack, Protelos must also not be used in patients with high blood pressure that is not properly controlled or in patients with a current or past history of any of the following: 
Kako bi se smanjio rizik od srčanog udara, lijek Protelos također se ne smije koristiti kod bolesnika s visokim krvnim tlakom koji se ne kontrolira ispravno ili kod bolesnika s trenutačnom ili prethodnom povijesti bolesti koja uključuje:
What is Protelos? 
Što je Protelos?
This showed that the risk of breaking a bone is reduced. 
To ukazuje na smanjenje rizika od prijeloma kosti.
As there has been some data showing an increased risk of heart attack with Protelos, the decision to prescribe Protelos should take into account the patient's individual heart risk. 
Budući da postoje podaci koji dokazuju povećani rizik od srčanog udara pri uporabi lijeka Protelos, pri donošenju odluke o propisivanju lijeka Protelos treba uzeti u obzir pojedinačni srčani rizik bolesnika.
This is a summary of the European public assessment report (EPAR) for Protelos. 
Ovo je sažetak Europskoga javnog izvješća o ocjeni dokumentacije (EPAR) za lijek Protelos.
What is the risk associated with Protelos? 
Koji su rizici povezani s lijekom Protelos?
The most common side effects with Protelos (which may affect more than 1 in 10 people) are hypersensitivity (allergic) skin reactions (rash, itching, urticaria or itchy rash, and swelling beneath the skin known as angioedema) and pain affecting muscles, bones and joints. 
Najčešće nuspojave s lijekom Protelos (koje se mogu pojaviti u više od 1 na 10 osoba) su kožne reakcije preosjetljivosti (alergijskog tipa) (osip, svrbež, koprivnjača i otekline ispod kože ili angioedem) i bolovi u mišićima, kostima i zglobovima.
When looking at results of the two studies taken together, fewer women in the Protelos group developed breaks at any site outside the spine (including the hip) than in the placebo group (331 out of 3,295 with Protelos compared with 389 out of 3,256 for placebo). 
Ako se gledaju rezultati dvaju ispitivanja zajedno, manje žena u skupini koja je uzimala Protelos doživjelo je prijelome na bilo kojem mjestu osim na kralježnici (uključujući kuk) nego u skupini koja je uzimala placebo (331 od 3295 s lijekom Protelos u usporedbi s 389 od 3256 za placebo).
Overall, the results of the second study taken alone were insufficient to demonstrate a benefit of Protelos in preventing bone breaks. 
Ukupno, ako se uzmu u obzir samo rezultati drugog ispitivanja, oni nisu bili dovoljni da bi pokazali korist lijeka Protelos u sprječavanju prijeloma kostiju.
Protelos must not be used in patients who have or have had venous thromboembolic events (problems due to the formation of blood clots in the veins, such as in the legs or lungs). 
Protelos se ne smije koristiti kod bolesnika koji imaju ili su imali događaje venske tromboembolije (problemi zbog nastanka krvnih ugrušaka u venama, npr. u nogama ili plućima).
In addition, education materials are sent to patients and healthcare professionals prescribing Protelos reminding them of the risk of heart and circulatory problems with the medicine and of the need for regular monitoring. 
Uz to, bolesnicima i zdravstvenim djelatnicima koji propisuju lijek Protelos šalju se edukativni materijali kojima ih se podsjeća na rizik od srčanih i krvožilnih problema s lijekom te na potrebu redovitog nadzora.
A risk management plan has been developed to ensure that Protelos is used as safely as possible. 
Pripremljen je plan upravljanja rizikom kako bi se osigurala što sigurnija primjena lijeka Protelos.
For more information about treatment with Protelos, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Više informacija o terapiji lijekom Protelos pročitajte u uputama o lijeku (također dio EPAR-a) odnosno obratite se svom liječniku ili ljekarniku.
In both studies, Protelos was compared with placebo (a dummy treatment) and the main measure of effectiveness was the reduction in the risk of a new bone break with Protelos. 
U oba ispitivanja Protelos se uspoređivao s placebom (liječenje bez djelatne tvari), a glavna mjera učinkovitosti bilo je smanjenje rizika novog prijeloma kostiju s lijekom Protelos.
What benefit has Protelos shown during the studies? 
Koje su koristi lijeka Protelos dokazane u ispitivanjima?
In the first study, this was based on the number of patients who, over three years, developed a new break in the spine, and in the second study, it was based on the number of patients who had a new bone break due to osteoporosis at any site other than the spine. 
U prvom ispitivanju, ova se mjera temeljila na broju ispitanica koje su tijekom tri godine doživjele novi prijelom kralježnice, a u drugom ispitivanju temeljila se na broju ispitanica koje su doživjele novi prijelom kosti zbog osteoporoze na bilo kojoj kosti osim na kralježnici.
In the first study, Protelos reduced the risk of new breaks in the spine by 41% over three years: 21% of the 719 women who took Protelos developed a new break in the spine, compared with 33% of the 723 who took placebo. 
Protelos je smanjio rizik od novih prijeloma kralježnice za 41 % tijekom tri godine: 21 % od 719 žena koje su uzimale Protelos doživjelo je novi prijelom kralježnice, u usporedbi s 33 % od 723 žene koje su uzimale placebo.
Protelos has also been compared with placebo in a main study involving 261 male patients at increased risk of breaking a bone. 
Protelos se također uspoređivao s placebom u glavnom ispitivanju koje je obuhvatilo 261 ispitanika s povećanim rizikom od prijeloma kostiju.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Protelos, including the appropriate precautions to be followed by healthcare professionals and patients. 
Na temelju tog plana u sažetak opisa svojstava lijeka kao i u uputu o lijeku, za lijek Protelos uključene su sigurnosne informacije, uključujući odgovarajuće mjere opreza kojih se zdravstveni djelatnici i bolesnici trebaju pridržavati.
Protelos is a medicine that contains the active substance strontium ranelate. 
Protelos je lijek koji sadrži djelatnu tvar stroncijev ranelat.
In the study in male patients, the bone density in the lower part of the spine increased by 7% after one year of treatment in patients taking Protelos, compared with an increase of 1.7% in patients taking placebo. 
U ispitivanju s ispitanicima, gustoća kostiju u donjem dijelu kralježnice povećala se za 7 % nakon jedne godine liječenja kod ispitanika koji su uzimali Protelos, u usporedbi s povećanjem od 1,7 % kod ispitanika koji su uzimali placebo.
Protelos is used to treat severe osteoporosis (a disease that makes bones fragile) in post-menopausal women and men who have a high risk of fracture and cannot be treated with other medicines approved for osteoporosis. 
Protelos se koristi za liječenje teške osteoporoze (bolesti koja može dovesti do prijeloma kostiju) kod žena u poslijemenopauzi i muškaraca s visokim rizikom za nastanak prijeloma i ne može se koristiti s drugim lijekovima kojima se liječi osteoporoza.
Protelos has been studied in almost 7,000 elderly women in two large studies. 
Protelos se ispitivao u dva velika ispitivanja koja su obuhvatila gotovo 7 tisuća žena starije dobi.
Why has Protelos been approved? 
Zašto je lijek Protelos odobren?
The CHMP decided that Protelos's benefits are greater than its risks and recommended that it be given marketing authorisation. 
Povjerenstvo za lijekove za primjenu kod ljudi (CHMP) odlučilo je da koristi od lijeka Protelos nadmašuju s njim povezane rizike te je preporučilo njegovo odobrenje za stavljanje u promet.
The active substance in Protelos, strontium ranelate, acts on the bone structure. 
Djelatna tvar lijeka Protelos, stroncijev ranelat, djeluje na strukturu kostiju.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Protelos. 
Committee for Medicinal Products for Human Use) ocijenilo lijek da bi preporučilo njegovo odobrenje za stavljanje u promet te uključuje preporuke Povjerenstva o uvjetima za primjenu lijeka Protelos.
What is Protelos used for? 
Za što se Protelos koristi?
How is Protelos used? 
Kako se Protelos koristi?
For the full list of all side effects reported with Protelos, see the package leaflet. 
Potpuni popis nuspojava zabilježenih pri primjeni lijeka Protelos potražite u uputi o lijeku.
How has Protelos been studied? 
Kako se Protelos ispitivao?
How does Protelos work? 
Kako djeluje Protelos?
In postmenopausal women, Protelos reduces the risk of vertebral and hip fractures. 
Protelos smanjuje rizik od prijeloma kralježnice i kukova kod žena u poslijemenopauzi.
These products are not widely authorised in the European Union and therefore availability of data is limited. 
Ti lijekovi nisu odobreni u cijeloj Europskoj uniji te je stoga dostupnost podataka ograničena.
The mechanism of action is not fully understood. 
Mehanizam djelovanja nije potpuno jasan.
2017, Vol. 27, 3, pp. 269-273. 
27, 3, pp. 269-273.
Thus, the more intrusive intramuscular injections could be avoided as intravenous administration is seen as a suitable alternative option. 
Stoga bi se invazivnije intramuskularne injekcije mogle izbjegavati jer se intravenska primjena smatra prikladnijom alternativnom mogućnošću.
It is available as monocomponent but also available in several combination products. 
Dostupan je kao jednokomponentni preparat, ali i u više kombiniranih lijekova.
1 Fieler M et al. Metamizole for postoperative pain therapy in 1177 children: A prospective, multicentre, observational, postauthorisation safety study. 
Metamizole for postoperative pain therapy in 1177 children: A prospective, multicentre, observational, postauthorisation safety study.